AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
5.71
-0.22 (-3.71%)
At close: Dec 29, 2023, 4:00 PM
5.88
+0.17 (2.98%)
After-hours: Dec 29, 2023, 7:44 PM EST
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $20, which predicts an increase of 250.26%. The lowest target is $6.00 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ABCL stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 2 |
| Buy | 5 | 4 | 4 | 5 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Initiates $6 | Buy | Initiates | $6 | +5.08% | Dec 5, 2023 |
| Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +250.26% | Oct 13, 2023 |
| Benchmark | Benchmark | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +110.16% | Aug 31, 2023 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $27 → $24 | Strong Buy | Maintains | $27 → $24 | +320.32% | Aug 4, 2023 |
| Credit Suisse | Credit Suisse | Buy Maintains $34 → $28 | Buy | Maintains | $34 → $28 | +390.37% | May 5, 2023 |
Financial Forecast
Revenue This Year
39.42M
from 485.42M
Decreased by -91.88%
Revenue Next Year
62.04M
from 39.42M
Increased by 57.39%
EPS This Year
-0.48
from 0.50
EPS Next Year
-0.63
from -0.48
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | 47.5M | 82.6M | 118.5M | 166.2M | 231.4M | 335.0M |
| Avg | 39.4M | 62.0M | 78.9M | 97.6M | 136.0M | 182.6M |
| Low | 33.2M | 43.9M | 47.0M | 61.7M | 70.6M | 85.3M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -90.2% | 109.6% | 90.9% | 110.7% | 137.2% | 146.4% |
| Avg | -91.9% | 57.4% | 27.1% | 23.7% | 39.4% | 34.3% |
| Low | -93.2% | 11.4% | -24.2% | -21.7% | -27.7% | -37.3% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -0.45 | -0.46 | -0.45 | -0.27 | -0.22 | 0.09 |
| Avg | -0.48 | -0.63 | -0.68 | -0.34 | -0.21 | 0.09 |
| Low | -0.53 | -0.84 | -0.90 | -0.40 | -0.21 | 0.09 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | - |
| Avg | - | - | - | - | - | - |
| Low | - | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.